News | Antiplatelet and Anticoagulation Therapies | January 17, 2017

Changes to Hospital Electronic Health Records Could Improve Care of Warfarin Patients

Study finds switching from paper records greatly improved physician-patient communication on medication therapy guidelines

electronic health records, EHR, warfarin therapy management, University of Missouri Health Care, blood thinner

January 17, 2017 — Warfarin is a commonly prescribed blood thinner used to prevent harmful blood clots. However, the drug requires frequent monitoring, daily dosing and can result in serious negative effects when mixed with vitamin K, a vitamin commonly found in vegetables such as lettuce or broccoli. Now, a new study from University of Missouri Health Care has found that using electronic health records (EHR) can improve the care patients receive after they leave the hospital and eliminate potential confusion among care providers and pharmacists.

“Previous research indicates that adverse effects of warfarin accounted for 33 percent of annual emergency hospitalizations for patients 65 or older in the United States,” said Margaret Day, M.D., a primary care physician and medical director at MU Health Care’s Family Medicine-Keene Clinic. “At MU Health Care, we designed the Outpatient Warfarin Management Order record in response to The Joint Commission’s call for institutions to reduce possible patient harm associated with the use of warfarin."

Day said that before the intervention, physicians would give patients warfarin management plans on paper forms, which made it difficult for providers to obtain that information later. Paper forms also sometimes caused confusion among pharmacists, physicians and patients since the warfarin plans could change frequently, according to Day.

MU Health Care currently uses an EHR that generates a comprehensive health summary for each admitted patient. Day said that her team found the discharge summary to be a valuable tool to communicate the key elements needed for patients and health providers to manage warfarin therapy.

“The information entered is visible to the patients and their community healthcare providers,” Day said. “In addition, the record also coordinates communication to pharmacy services for any dosage updates.”

Before implementing the new record, Day’s team found that 42 percent of patients’ discharge charts included key elements for discharging patients on warfarin. After the intervention, the team found that percentage nearly doubled, to 78 percent. In addition, physicians and pharmacists who used the new record were surveyed.

“Of the 28 physicians and pharmacists who took part in the survey, 61 percent said that the new warfarin order was user-friendly and accessible,” Day said.

Day said that this study demonstrates the EHR’s potential value in assisting with warfarin or anticoagulation therapy between outpatient and inpatient settings and across multiple providers. In addition, Day said the new process not only provides notification about the transition care to patients’ referring health providers in their communities, but also facilitates collaborative care with pharmacies.

The project, “Improving Transitions of Care for Hospitalized Patients on Warfarin,” was published in The Joint Commission Journal on Quality and Patient Safety.

For more information: www.jcrinc.com

Related Content

Daily Aspirin Use May Do More Harm Than Good for Healthy People
News | Antiplatelet and Anticoagulation Therapies | December 17, 2018
Among otherwise healthy people, a daily dose of aspirin does not save lives and causes additional bleeding, a new...
Experimental Vaccine May Reduce Post-Stroke Blood Clot Risk
News | Antiplatelet and Anticoagulation Therapies | November 01, 2018
A vaccine may one day be able to replace oral blood thinners to reduce the risk of secondary strokes caused by blood...
Thrombolytic Science Initiates Phase 2 Trial of Novel Ischemic Stroke Treatment Regimen
News | Antiplatelet and Anticoagulation Therapies | September 07, 2018
A new Phase 2 clinical trial looks to confirm the efficacy and safety of Thrombolytic Science LLC’s (TSI) sequential...
Bleeds and Benefit With Aspirin Balanced in Diabetes Patients
News | Antiplatelet and Anticoagulation Therapies | September 05, 2018
Aspirin prevented serious vascular events in patients with diabetes who did not already have cardiovascular disease,...
Extended Post-Hospital Oral Anticoagulant Use Reduces Non-Fatal Blood Clots
News | Antiplatelet and Anticoagulation Therapies | August 31, 2018
Use of an oral anticoagulant in medically ill patients for 45 days following hospital discharge reduces the rate of non...
AFib Patients Want More Information About Anticoagulation Reversal
News | Antiplatelet and Anticoagulation Therapies | June 27, 2018
Results from a 902-person, five-country survey of people living with atrial fibrillation (AF) reinforce the importance...
Lower Oral DOAC Anticoagulant Use Associated With More Thromboembolic Events Than Warfarin. #HRS 2018
News | Antiplatelet and Anticoagulation Therapies | May 18, 2018
May 18, 2018 — Nearly half of patients prescribed warfarin and just under one third of those using newer direct oral
The U.S. Food and Drug Administration (FDA) has approved Portola Pharmaceuticals' Andexxa, the first antidote indicated for patients treated with rivaroxaban (Xarelto) and apixaban (Eliquis), when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.

The U.S. Food and Drug Administration (FDA) has approved Portola Pharmaceuticals' Andexxa, the first antidote indicated for patients treated with rivaroxaban (Xarelto) and apixaban (Eliquis), when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.

 

Feature | Antiplatelet and Anticoagulation Therapies | May 07, 2018
The U.S. Food and Drug Administration (FDA) has approved Portola Pharmaceuticals' Andexxa, the first antidote indicated...
The largest trial to date for short-term DAPT concluded the practice cannot be deemed safe due to a higher adverse event rate. Image courtesy of the American Heart Association. #ACC18

The largest trial to date for short-term DAPT concluded the practice cannot be deemed safe due to a higher adverse event rate. Image courtesy of the American Heart Association.

News | Antiplatelet and Anticoagulation Therapies | March 19, 2018
The combined rate of death from any cause, heart attack or stroke within 18 months was not significantly different in...
Overlay Init